Life Sciences M&A: Private Target Deal Trends

This webinar highlights the recently released SRS Acquiom 2019 Life Sciences M&A Study, which gives a detailed look at deal terms and earnout achievement rates by year, sector and stage of development. The study draws from our experience as a professional shareholder representative on more than 100 structured life sciences deals involving almost 1,000 milestones potentially worth over $30 billion.

The webinar discussion points include:

  • Key issues in negotiating these agreements
  • Best practices for optimizing outcomes after the deal is announced
  • An analysis of which milestones actually get paid, and when

This webinar was produced in partnership with the NVCA and was recorded on November 12, 2019.\

Duration: 58 minutes


  • Don Morrissey – Head of Life Sciences
  • Sara Wilcox – Executive Director, Contract Administration

Don Morrissey

Head of Life Sciences 303.250.8936

Don advises life science clients on M&A deal negotiations and post-closing milestones and earnouts. He is principal author of our life science studies and a frequent speaker at industry events.

Before joining SRS Acquiom, Don spent more than a decade helping to grow two venture-backed life science start-up companies through IPOs. He has been responsible for many strategic transactions involving licensing, partnering and M&A, as well as financings with leading venture capital and private equity firms. He was formerly SVP, Corporate Development and General Counsel for Replidyne, an antibiotic drug development company, and VP, Legal Affairs and Business Development for Caliper Life Sciences, a microfluidics company. He began his career as a business attorney with Cooley LLP.

Don holds a law degree from USC and a BA in Molecular, Cellular and Developmental Biology from the University of Colorado.

Gain the SRS Acquiom edge on your next deal.

Get Started